As several COVID-19 vaccine candidates are now in the late phase of clinical trials, MHE is sharing a few stories that have covered the infamous virus' vaccine development journey.
Several candidates for a COVID-19 vaccine are now in late-phase clinical trials, and the world is eagerly awaiting results. Managed Healthcare Executive® has covered the race to develop a safe and effective vaccine from the beginning of the pandemic.
Here are a few of our top stories:
- Word From FDA, NIH on COVID-19 Vaccine: No Cutting Corners
FDA outlines what it will take to get a COVID-19 vaccine approved, while NIH offers its research strategy.
- ICER's Gaze Turns to COVID Vaccine, Treatment Prices
The Institute for Clinical and Economic Review (ICER) is jumping into the fray of putting a price on what the world is waiting for — a safe, effective COVID-19 vaccine.
- The Pharmaceutical Industry’s Role in a COVID-19 Vaccine
Drug makers around the world are racing to develop the first effective COVID-19 vaccine. Early efforts show promise, but an anticipated jump in the novel coronavirus cases in the fall means the sooner a vaccine is developed, the more lives can be saved-and the pharmaceutical industry plays a major role in this discovery.
- An Update on COVID-19 Vaccine Development
A safe, effective vaccine by December 2020 or January 2021?
-The Search is on For Treatment Drugs and a Vaccine
Testing remains ongoing in the search for treatment drugs and a vaccine for COVID-19.
Related to the coverage of the race to develop a COVID-19 vaccine, MJH Life Sciences will be hosting a COVID-19 vaccine webinar 7/30 at 6 pm ET. Panelists will review the top vaccine candidates & discuss how to combat the logistical challenges of rolling out a vaccine during a global pandemic. Learn more & register here.